Valvular & structural heart diseaseRandomised controlled trial
Five-Year Follow-Up of Transcatheter Aortic Valve Replacement With Self-Expanding Intra-Annular Versus Commercially Available Valves
- Randomised controlled trial (5-year follow-up of the PORTICO IDE trial)
- multicentre
- 1:1 randomisation
Authors' conclusion
In patients at high or extreme surgical risk, TAVR with the self-expanding intra-annular transcatheter heart valve had similar 5-year overall survival, stroke rates, and valve function compared with commercially available valves.
Study context
- Population
- Severe symptomatic AS at high/extreme surgical risk
- Participants
- 750 participants
- Comparison
- Study valve vs CAV
- Study valven = 381
- CAVn = 369reference
- Primary endpoint
- Prespecified clinical outcomes and hemodynamic valve parameters (primary safety and efficacy endpoints previously reported)
- Follow-up
- 5 years
Primary result
As reported in the abstract
All-cause mortality or stroke
P = 0.42
Further findings
CV mortality · 5 years · numerically higher with study valve
P = 0.06
Mean transvalvular gradient · 5 years
P = 0.008
Valve area · 5 years
P = 0.40
Safety
New permanent pacemaker implantation · 5 years
P < 0.0001
Original publication
Five-Year Follow-Up of Transcatheter Aortic Valve Replacement With Self-Expanding Intra-Annular Versus Commercially Available Valves. JACC Cardiovasc Interv. Published 1 September 2026. doi:10.1016/j.jcin.2026.05.032
Summarised from the published abstract; every number is checked against it